Our findings add to the body of evidence supporting that targeting of the cellular protein G3BP1 can be used as an antiviral approach and validates the use of PROTACs for the efficient and specific degradation of cellular factors as a feasible methodology to combat viral diseases. This evidence concerns the gene G3BP1 and viral load.